The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

The growing incidence of infectious diseases, cancer, and chronic illnesses has substantially increased the demand for ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.

mResvia’s prescribing information indicates that the vaccine was 78.7% effective at preventing RSV that presents with two or more symptoms at 3.7 months of follow-up – a little lower than ...

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...